Beneforti, L., Chinnici, A., Coniglio, M., Papa, M., Punzi, L., Sieni, E., et al. (2024). Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAFV600E clone in a newborn affected by high-risk Langerhans cell histiocytosis. BRITISH JOURNAL OF HAEMATOLOGY, 205(3), 1234-1237 [10.1111/bjh.19637].

Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAFV600E clone in a newborn affected by high-risk Langerhans cell histiocytosis

Beneforti L.;
2024

Lettera in rivista
high-risk Langerhans cell histiocytosis
English
10-lug-2024
2024
205
3
1234
1237
none
Beneforti, L., Chinnici, A., Coniglio, M., Papa, M., Punzi, L., Sieni, E., et al. (2024). Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAFV600E clone in a newborn affected by high-risk Langerhans cell histiocytosis. BRITISH JOURNAL OF HAEMATOLOGY, 205(3), 1234-1237 [10.1111/bjh.19637].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/510459
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact